« Back
Home /
Rosuvastatin

Rosuvastatin

Item no.	HY-17504A-10mM
Manufacturer	MedChem Express
CASRN	287714-41-4
Amount	10 mM
Category	Oncology Neuroscience Neuroinflammation Metabolism Diabetes Glucose Homeostasis Cholesterol & Lipid Metabolism Neural Adhesion Molecules Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer
Type	Inhibitors
Specific against	other
Purity	99.67
Citations	[1]Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5(2): p. 437-44.\|[2]Plante I, et al. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012 Feb;101(2):868-78.\|[3]Feng PF, et al. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Mol Pharm. 2019 Apr 1;16(4):1477-1488.\|[4]Carswell C.I., et al. Rosuvastatin. Drugs, 2002. 62(14): p. 2075-85; discussion 2086-7. ACS Omega. 2025 Oct 29;10(44):52562–52575. Biomed Pharmacother. 2025 Oct 21:192:118665. Biosens Bioelectron. 2025 Nov 15:288:117807. Eur J Pharmacol. 2023 Sep 15:955:175911. Exp Ther Med. 2021 Oct;22(4):1189. Front Cell Dev Biol. 2021 May 6;9:651579. Front Oncol. 2021 May 10:11:595285. J Inflamm Res. 2021 Apr 16:14:1537-1549. J Nephropharmacol. 2025 Sep 20:e12798 Phytomedicine. 2024 Apr 10, 155621. Vasc Endovasc Rev. 2025 Nov 7. World J Methodol. 2025 Jun 20;15(2):99580. Acta Pharmacol Sin. 2023 Jul;44(7):1416-1428. Adv Sci (Weinh). 2024 Jul 5:e2403451. bioRxiv. 2024 November 08. Cell Death Discov. 2024 May 29;10(1):263. Cell Metab. 2025 Sep 2;37(9):1907-1925.e14. Cell Signal. 2025 Jul:131:111753. Front Bioeng Biotechnol. 2022 Mar 17;10:826093. Front Cell Dev Biol. 2022 Mar 3;10:806081. MedComm (2020). 2024 Aug 31;5(9):e681. Pharm Res. 2025 Oct 27. Phytomedicine. 2025 Jun 19:145:157014.
Smiles	O=C(O)C[C@H](O)C[C@H](O)/C=C/C1=C(C(C)C)N=C(N(C)S(=O)(C)=O)N=C1C2=CC=C(F)C=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ZD 4522
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound1
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Product Description	Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks hERG current with an IC50 of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3].
Manufacturer - Research Area	Metabolic Disease; Cardiovascular Disease; Cancer
Solubility	DMSO : ≥ 100 mg/mL
Manufacturer - Pathway	Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease
Clinical information	Launched
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.